<DOC>
	<DOCNO>NCT02233998</DOCNO>
	<brief_summary>The reduction exist plaque gum inflammation evaluate use two market mouth rinse along tooth brush 21 day use compare placebo mouth rinse . 165 healthy volunteer enrol three week study . Volunteers qualify study equal chance assign one three treatment group . Volunteers total three visit include 1 ) Screening/Baseline Day 1 2 ) Day 11 ( 10 day use ) 3 ) Day 22 ( 21 day use ) . Volunteers maintain diary home record treatment use ask come clinic without brush use product least 8 hour , 18 hour . Examinations oral hard/soft tissue , gingivitis , bleed plaque assessment complete Screening/Baseline repeat Clinic Visit 3 , Day 22 .</brief_summary>
	<brief_title>A Clinical Trial Test Effect Marketed Mouth Rinses Decreasing Plaque Gum Inflammation</brief_title>
	<detailed_description>A sufficient number generally healthy subject ( approximately 165 ) meet require inclusion/exclusion criterion enrol 21 day , examiner-blind , single center , randomize , parallel-group control clinical trial ensure least 150 subject ( 50 per treatment group ) complete study . At baseline , prescreened subject present clinic site baseline examination ( oral tissue assessment , gingivitis , bleed plaque assessment ) refrain oral hygiene least 8 hour , 18 hour . After baseline oral examination , assessment inclusion/exclusion criterion qualify subject randomly assign one three treatment group . Immediately follow randomization , subject begin use assign test product follow label instruction . If randomize control group , subject brush twice daily usual manner ADA accept fluoride toothpaste soft bristle toothbrush follow rinsing twice daily 5 % hydroalcohol control rinse ( W002194-221P ) . If randomize active treatment group ; subject brush twice daily usual manner , follow rinsing twice daily assign mouth rinse formulation ( 19292-116A 11965-059 ) . Subjects instruct follow label instruction 20ml 30 second twice daily mouth rinse product . The first product use conduct supervision study personnel . All brush rinse unsupervised subject require maintain diary card document twice daily product use , brush rinse time . Compliance evaluate weigh residual volume return mouth rinse review subject diary . Subjects receive ADA- accept fluoride-containing dentifrice soft bristle toothbrush baseline visit . Subjects may continue use floss remove impact food teeth part usual oral care regimen course study ; oral hygiene procedure permit , include teeth cleaning , whiten dental procedure except emergency treatment . The decision withdraw subject due emergency dental treatment occur discretion Investigator . At baseline three week ( ±2 day ) visit , subject brush used product least 8 hour , 18 hour . Oral tissue safety , Modified Gingival Index ( MGI ) , Bleeding Index ( BI ) , Plaque Index ( PI ) assess .</detailed_description>
	<mesh_term>Gingivitis</mesh_term>
	<mesh_term>Listerine</mesh_term>
	<mesh_term>Sodium Fluoride</mesh_term>
	<criteria>Inclusion Criteria 1 . Able comprehend follow requirement study ( include availability schedule visit date ) base upon research site personnel 's assessment ; 2 . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial ; 3 . Males females 18 year age old , good general oral health without know allergy commercial dental product ; 4 . A minimum 20 natural teeth scorable facial lingual surface . Teeth grossly carious , extensively restore , orthodontically band , abutment , exhibit severe generalize cervical and/or enamel abrasion , third molar include tooth count ; 5 . A mean gingival index ≥ 1.95 accord Modified Gingival Index ; 6 . A mean plaque index ≥ 1.95 accord Turesky modification QuigleyHein Plaque Index score six surface per tooth ; 7 . Absence significant oral soft tissue pathology , exclude plaqueinduced gingivitis , base visual examination discretion Investigator ; 8 . Absence moderate/advanced periodontitis base clinical examination ( ADA Type III , IV ) . 9 . Absence fix removable orthodontic appliance removable partial denture ; 10 . Able read understand local language ; 11 . Male nonpregnant , nonlactating female , selfreport ; 12 . Male female subject reproductive potential must agree practice medically acceptable form birth control study 30 day follow last dose investigational product . Females must use birth control least 3 month prior Baseline visit . Medically acceptable form birth control may use subject and/or his/her partner include : Abstinence reproductive intercourse line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptomthermal , postovulation method ) withdrawal acceptable method contraception ; Established use hormonal method contraception ( oral , injected , implanted , patch vaginal ring ) ; Intrauterine device ( IUD ) intrauterine system ( IUS ) ; Barrier method contraception spermicide : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ; Surgical sterilization ( e.g. , vasectomy confirm effective sperm count check , tubal occlusion , hysterectomy , bilateral salpingectomy ) ; A female subject postmenopausal ( i.e. , amenorrheic least 12 month prior Baseline visit ) consider reproductive potential . 13 . Willing investigational product use time period ; 14 . Willing able comply study procedure attend schedule visit duration study . Subjects present follow include study : 1 . History significant adverse effect , include sensitivity suspect allergy , follow use oral hygiene product toothpastes mouth rinse red food dye ; 2 . Dental prophylaxis within 2 week prior Screening visit ; 3 . Antibiotic , antiinflammatory anticoagulant therapy study within one month prior baseline exam ; 4 . Regular use chemotherapeutic antiplaque/antigingivitis product triclosan , essential oil , cetylpyridinium chloride , chlorhexidine contain mouth rinse within three week prior baseline ; 5 . Selfreported pregnancy lactation ( criterion due oral tissue change relate pregnancy nurse affect interpretation study result ) ; 6 . Significant unstable uncontrolled medical condition may interfere subject 's participation study , discretion Investigator ; 7 . Participation clinical study within 30 day Visit 1 ; 8 . Subjects related person involve directly indirectly conduct study ( i.e. , principal investigator , subinvestigators , study coordinator , site personnel , employee Johnson &amp; Johnson subsidiary , contractor Johnson &amp; Johnson , family ) ; 9 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation , substance alcohol abuse may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Plaque</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Gums</keyword>
	<keyword>Gingiva</keyword>
	<keyword>Gingival Inflammation</keyword>
	<keyword>Gingival Bleeding</keyword>
</DOC>